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Abstract
Cervical carcinomas result from cellular transformation by the human papillomavirus (HPV) E6 and E7 oncogenes which are
constitutively expressed in cancer cells. The E6 oncogene degrades p53 thereby modulating a large set of p53 target genes
as shown previously in the cervical carcinoma cell line HeLa. Here we show that the TAp63b isoform of the p63 transcription
factor is also a target of E6. The p63 gene plays an essential role in skin homeostasis and is expressed as at least six isoforms.
One of these isoforms, DNp63a, has been found overexpressed in squamous cell carcinomas and is shown here to be
constitutively expressed in Caski cells associated with HPV16. We therefore explored the role of p63 in these cells by
performing microarray analyses after repression of endogenous E6/E7 expression. Upon repression of the oncogenes, a
large set of p53 target genes was found activated together with many p63 target genes related to cell adhesion. However,
through siRNA silencing and ectopic expression of various p63 isoforms we demonstrated that TAp63b is involved in
activation of this cell adhesion pathway instead of the constitutively expressed DNp63a and b. Furthermore, we showed in
cotransfection experiments, combined with E6AP siRNA silencing, that E6 induces an accelerated degradation of TAp63b
although not through the E6AP ubiquitin ligase used for degradation of p53. Repression of E6 transcription also induces
stabilization of endogenous TAp63b in cervical carcinoma cells that lead to an increased concentration of focal adhesions at
the cell surface. Consequently, TAp63b is the only p63 isoform suppressed by E6 in cervical carcinoma as demonstrated
previously for p53. Down-modulation of focal adhesions through disruption of TAp63b therefore appears as a novel E6-
dependent pathway in transformation. These findings identify a major physiological role for TAp63b in anchorage
independent growth that might represent a new critical pathway in human carcinogenesis.
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Introduction
Infection of the anogenital mucosal epithelium with high risk
Human Papilloma Virus (HPV) is linked to 99% of cervical
carcinomas [1]. Cell lines derived from these cervical carcinomas
remain associated with HPV and contain part of the viral genome
integrated in the cellular genome. However, not all viral genes are
retained in this integration; the E6 and E7 oncogenes remain,
while the open reading frames encoding viral proteins E1 and E2,
necessary for viral DNA replication, are disrupted [2,3]. We have
previously used the HPV18-associated HeLa cell line to study
transcriptional modulation of viral and cellular genes following
repression of the E6 and E7 oncogenes, and found that a large
number of cellular genes were in fact modulated via E6 and E7
[4,5]. Of particular interest was the discovery that genes targeted
by either p53 or E2F were respectively activated or repressed
through repression of E6 and E7 [4].
We now wish to develop and extend these findings. In particular
we are interested in the potential effect of HPV E6 and E7 on
other less well defined members of the p53 family. The p73 and
p63 transcription factors are more recently discovered p53 family
members, and although they share structural homology with p53
and are able to interact with similar DNA binding motifs, they
modulate different regulatory pathways [6–9]. While p53 is a
tumor suppressor and does not obviously participate in embryonic
development, p63 and p73 on the contrary are strongly linked to
embryonic development in mice [10,11].
The critical developmental role of p63 is illustrated in null mice,
which do not survive beyond few days after birth and exhibit limb
truncation and a striking absence of skin [10,11]. Human genetic
syndromes with comparable phenotypes have also been linked to
p63, including EEC syndrome (Ectrodactyly Ectodermal dysplasia
Clefting), ADULT (Acro-Dermato-Ungual-Lacrimal-Tooth mal-
formations), LMS (Limb-Mammary syndrome), Hay Wells
syndrome, SHFM (Split-hand/foot malformations), and Rapp-
Hodgkin Syndrome, reviewed in [12]. These findings of a crucial
role of p63 in skin development were supported by its specific
expression pattern in epithelia [13]. There is also evidence that
p63 may play a role in cancer since it has been shown to be
overexpressed in squamous cell carcinomas [14]. In addition, the
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of genes, which differ from p53 target genes [15–19]. One specific
cluster of p63 target genes is related to cellular adhesion and
contains either cell: matrix or cell: cell adhesion genes such as
integrins, and components of the ECM, desmosomes or tight
junctions.
Interpreting the potential role of p63 in cancer is complicated
by the existence of six isoforms of the transcription factor. The p63
gene contains two promoters driving the production of distinct
proteins, one with an N-terminal transactivation domain (TAp63)
and one without (DNp63). Moreover, each of these two proteins
may be expressed as a, b and c isoforms, exhibiting particular
expression patterns and characteristics. For example, DNp63a is
abundantly expressed in proliferating keratinocytes of the
epithelial basal layers, while the TA isoforms are not detectable
in skin [20]. The DNp63a isoform is also increased in squamous
cell carcinomas [13], thus supporting its proliferative functions. In
contrast, TAp63 has recently been described as preventing
premature aging by promoting adult stem cell maintenance in
mice, linking its activities to DNA repair and wound healing rather
than to differentiation [21]. Although this isoform of p63 is able to
functionally interact with DNp63, p73 and p53, it also displays a
specific role as transcriptional modulator of its own target genes
such as the kinase inhibitor p57
kip2 [21]. Roles of the various p63
isoforms as well as p53 and p73 in skin proliferation and
differentiation are not yet fully understood. Additional complexity
comes from the fact that they are able to compensate each other to
some extent, as demonstrated for example by the increase of p63
expression in the skin of the p53 -/- mice [22]. They are also able
to regulate each other, although these cross regulations are not yet
fully understood and involve transcriptional as well as post
transcriptional mechanisms [23].
Here we show that repression of the E6/E7 oncogenes induces
transcriptional activation of a large set of potential p63 target
genes in the HPV16-associated cervical carcinoma Caski cell line.
We demonstrate, through siRNA silencing and direct over-
expression of various p63 isoforms, that some of these genes are
indeed p63 targets, mostly responsive to TAp63b and not to the
constitutively expressed DNp63a and b isoforms. Furthermore we
showed that the stability of the TAp63b isoform is down-
modulated by E6, thus functionally linking repression of p63
target genes to expression of the E6 oncogene in cervical
carcinoma cells. Over-expression of TAp63b or repression of
E6, both induce increase in focal adhesion in cervical carcinoma
cell lines. These data emphasize a new role of the TAp63b isoform
in activating cell adhesion in epithelial cells and of the E6
oncogene in down-modulating this pathway in cervical cancer.
Results
Expression of p63 isoforms in cervical carcinoma and
keratinocyte cell lines
We wished to understand whether a p63-mediated adhesion
pathway might be important in the HPV16-associated cervical
carcinoma Caski cell line and how these cells express p63
compared to HeLa cells and non transformed human keratinocyte
cell lines. Levels of mRNA for the DN and TA isoforms of p63
were measured by Real Time PCR in HeLa and Caski cancer cell
lines, compared to the non HPV-associated keratinocyte cell lines
HaCaT and N-Tert. Low levels of transcripts (around 28 ct) of the
TAp63 isoforms were detected in all four cell lines, while transcript
levels of the DNp63 isoforms varied from very low in HeLa cells
(30 ct) to markedly higher levels in the HaCaT, N-Tert (around 18
ct) and Caski cells (around 20 ct) (Figure 1A). In HeLa cells, no
endogenous p63 isoforms were detected at the protein level, as
expected from the low levels of transcription (data not shown). We
took advantage of this and used HeLa cells transfected with
expression vectors of the different p63 isoforms as a comparison to
study endogenous p63 protein levels in the other cell lines. Only 2
isoforms of DNp63 (a and b) were consistently detected in N-Tert,
HaCaT and Caski cell extracts with an expression level of
DNp63a between 1,5 and 2 times higher in non HPV-associated
keratinocytes than in Caski (Figure 1B). Under similar conditions,
TAp63 isoforms were not detectable in any of these cell extracts.
However, low levels of TAp63 were detected with the use of a
purified antibody against the TA domain of p63. Caski cells
express mainly the TAp63b isoform while HaCaT cells express
both b and c isoforms and N-Tert and primary keratinocytes
mainly the c isoform with very low levels of the b isoform
(Figure 1C).
Repression of HPV16 E6/E7 transcription modulates a
p63 pathway in Caski cells
In a previous study we described the modulation of putative p63
target genes in HeLa cells following HPV18 E6/E7 repression [5].
This occurred in the absence of detectable endogenous p63
expression; therefore we asked whether the range of p63 target
genes modulated might be greater in Caski cells, which express
significant levels of endogenous p63. A truncated form of the HPV
protein E2 efficiently represses E6/E7 transcription in HeLa cells
[4], and thus may be exploited as a reagent to study the effects of
their inhibition. We used Affymetrix microarrays to study gene
modulation in Caski cells infected by recombinant adenoviruses
expressing GFP or the GFP-E2 protein truncated of its
transactivation domain (E2C). As revealed by Real Time PCR,
E2C repressed E6/E7 transcription by more than 90% under
conditions where 100% of Caski cells were infected (Figure 2A).
We also verified the activation of the endogenous p53 target gene
p21 (8-fold) and the repression of the cell cycle gene cenpa (5-fold),
that have previously been shown to be modulated by repression of
E6/E7 in cervical carcinoma cells (Figure 2A) [5]. Gene
expression analysis in E6/E7-repressed Caski cells revealed
modulation of 825 genes: 463 repressed genes, including mitotic
genes and E2F target genes (data not shown), and 362 genes whose
Author Summary
High-risk human papillomavirus infection can cause cancer
of the uterine cervix. The viral proteins leading to
transformation of the infected keratinocytes are the E6
and E7 oncogenes which interact with and induce
degradation of the cell cycle regulators p53 and pRB. In
cervical carcinoma cells, repression of E6/E7 stabilizes the
p53 transcription factor leading to activation of a large
group of cellular p53 target genes. Here we show that
repression of E6/E7 also induces transcriptional activation
of an additional large set of genes involved in cell
adhesion including previously described p63 target genes.
Indeed, we further demonstrated that these p63 target
genes are activated by TAp63b and not by p53 or by the
DNp63a or b isoforms, even though these transcription
factors are also expressed in these cells. In cervical
carcinoma cells, E6 expression therefore leads to TAp63b
degradation thereby allowing anchorage independent
growth. Our work describes a new E6-dependent trans-
formation pathway in HPV-associated carcinogenesis.
TAp63b inhibition may also represent a common pathway
to activate anchorage independent growth in cancers.
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than 0.01 (data not shown). Using the TRANSFAC Professional
data base (Biobase) we assigned 52 of these activated genes to the
p53 pathway (Table S1) while 159 could be assigned to the p63
pathway (Table S2), with 36 genes overlapping with p53
(Figure 2B). In all, 123 exclusive p63 putative target genes were
Figure 1. Levels of expression of endogenous p63 isoforms in four keratinocyte cell lines. (A) Real-Time PCR analyses of endogenous
DNp63 and TAp63 isoforms performed in two cervical carcinoma cell lines, HeLa and Caski associated with HPV18 and HPV16 respectively, and two
immortalized keratinocyte cell lines not associated with HPV, N-Tert and HaCaT. Values given are Ct (Cycling threshold) with higher Ct corresponding
to lower mRNA levels; data are represented as mean 6 standard deviation (SD). Internal controls were mRNA levels of housekeeping genes HDAC,
GADPH and 18S rRNA. (B) Western blot analyses of endogenous levels of DNp63 isoforms in Caski, HaCaT and N-Tert cells compared to HeLa cells
transfected with the expression vectors of the different DNp63 isoforms (a, b and c) detected using a pan-p63 antibody (4A4 Pharmingen).
Quantification of the western blots indicated that N-TERT and HaCaT express 1.5 and 1.9-fold more DNp63a than Caski. (C) Western blot analyses of
endogenous levels of TAp63 isoforms in Caski, HaCaT, N-Tert, and human primary keratinocytes (HPK) using a purified specific TAp63 antibody
(Biolegend Poly 6189) compared to HeLa cells transfected with the vectors expressing the TAp63 isoforms a, b and c. Quantification of the western
blots indicated that HaCaT express 1.3-fold more TAp63b than Caski while the c isoform is expressed 2.3-fold more in HaCaT and N-Tert and 1.6-fold
more in HPK than in Caski.
doi:10.1371/journal.ppat.1002256.g001
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imately 20% have previously been allocated to adhesion pathways
[5,15] (Table S3 in Text S1).
To confirm up-regulation of an adhesion pathway upon
repression of E6 and E7 transcription, Caski cells infected with
the adenovirus encoding GFP-E2C compared to the GFP control
were subjected to gene expression analyses using a Human
extracellular matrix and adhesion molecules PCR array (SABios-
ciences). Repression of E6/E7 transcription by E2C induced a
strong response in genes involved in cellular adhesion in Caski
cells, with 34% of the genes present in the PCR-arrays activated
between 1.8 and 7-fold and 6% of genes repressed (Figure S1A in
Text S1). Silencing E6/E7 with siRNA was also efficient,
activating 53% of the PCR-arrays genes while only 3% were
repressed (Figure S1B in Text S1). Among the genes contained
within these arrays, 18 are known p63 targets. Half of these genes
were activated in both conditions of E6/E7 repression.
Modulation of putative p63 target genes by E6/E7 is
independent of both p53 and DNp63 isoforms
As siRNA was also effective in repressing E6/E7 transcription in
Caski cells (Figure S1B in Text S1), we used this technique to
further appreciate the effects of the HPV oncogenes on the p63
pathway. We used E6/E7 siRNA to silence mRNA expression of
Figure 2. Transcriptome analyses in Caski cells after E2C-induced transcriptional repression of E6 and E7. (A) Modulation of E6/E7, p21
(E6/p53 pathway) and cenpa (E7/E2F pathway) mRNA levels by Real-Time PCR in Caski cells infected by adenoviruses expressing GFP-E2C or GFP in
three independent experiments. Values given are the ratio of mRNA levels in E2C compared to GFP infected cells (mean 6 SD, *p , 0.05). (B)
Schematic representation of the modulation of cellular genes found in microarray experiments performed in Caski cells. Data were analyzed using
Partek Genomics Suite software which revealed a total of 825 modulated genes including 463 repressed and 362 activated genes. Using TRANSFAC
Professional software (Biobase), the list of activated genes was compared to p53 and p63 Chip on ChIP data.
doi:10.1371/journal.ppat.1002256.g002
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single polycistronic mRNA and cannot be silenced individually
[5]. Silencing of E6/E7 by about 60% did not affect levels of
endogenous DNp63 mRNA (Figure 3A). This was confirmed by
western blots, using a pan-p63 antibody (4A4), with pan-p63
siRNA (which silenced all p63 isoforms) and p53 siRNA as positive
and negative controls respectively (Figure 3B upper panel). The
p63 siRNA decreased p63 protein expression by about 50% while
the p53 siRNA decreased p53 expression by 80% as quantified
from the western blots shown in Figure 3B. In contrast, E6/E7
Figure 3. Modulation of a set of adhesion genes in Caski through E6/E7 silencing is dependent on p63. (A) Real-Time PCR of the E6/E7
oncogenes and DNp63 performed in Caski cells expressing E6/E7 siRNA compared with siRNA control where mRNA levels are given in arbitrary units
(a.u) with the control siRNA set up to 1000 (mean 6 SD, *p , 0.05). (B) Western blot analyses of endogenous DNp63 isoforms and p53 in Caski
expressing different siRNA showing silencing of all DNp63 isoforms (a, b and c) by the p63 siRNA (40 and 50% in the absence or presence of siE6/E7)
and 80% silencing of p53 by the p53 siRNA. A relative stabilization of p53 upon silencing of E6/E7 is also visible. (C) Modulation of mRNA levels of the
set of adhesion genes from (Table S3 in Text S1), following silencing of E6/E7. (D) Modulation of mRNA levels of the same set of genes following
silencing of p63 or p53. (E) Concomitant silencing of p63 and E6/E7 partially restored the basal levels of the adhesion genes but not of the p53 target
gene, p21. mRNA levels were obtained by RT-PCR and calculated as in panel A (mean 6 SD, *p , 0.05).
doi:10.1371/journal.ppat.1002256.g003
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stabilized even in the presence of cotransfected p63 siRNA
(Figure 3B lower panel). We then selected a group of the putative
p63 target genes identified as activated in the microarrays from the
list of genes given in (Table S3 in Text S1) and assessed their levels
of transcription following siRNA silencing of E6/E7. As expected,
these genes were activated between 3 and 4-fold following
silencing of E6 and E7 transcription, thus confirming the
microarray data (Figure 3C). Interestingly however, these
experiments lead to the conclusion that HPV16 E6/E7 cause
down regulation of putative p63 target genes without modulating
DNp63.
The fact that E6/E7 silencing did not affect DNp63 expression
while it stabilizes p53 (Figure 3B) led us to ask whether the cellular
target genes were indeed being modulated by p63. Direct silencing
of p63 by a pan-p63 siRNA induced up to 50% repression of the
set of target genes, except for the p53 target gene p21 (Figure 3D),
while silencing p53 did not strongly influence their expression
except in the case of notch1 and p21 (Figure 3D). We decided to
confirm whether activation of these genes following E6/E7
silencing occurred through p63 by concomitantly transfecting
the two siRNA. Cotransfection of Caski cells with the E6/E7 and
p63 siRNA induced a reversion of the gene activation seen with
the E6/E7 siRNA alone, thus indicating that these genes are
indeed mainly controlled by p63 (Figure 3E). Activation of p21 and
both notch and ceacam1 was either not or partially reversed by
cotransfection of p63 siRNA, confirming that p21 is mainly
activated by p53 in Caski cells, while notch1 and ceacam1 are
activated by both p63 and p53 as previously published for notch1
[24,25]. Therefore, although this panel of genes is indeed activated
by p63, the DN isoforms constitutively expressed in Caski cells
may not be directly involved in this regulation, since their
expression is not modulated upon E6/E7 silencing (Figure 3A and
3B upper panel). As the p63 siRNA was designed to repress both
DN and TA isoforms of p63, we therefore examined a possible role
for the TAp63 and specifically of the beta isoform that is expressed
in Caski cells (Figure 1C).
The p63 target genes are directly activated by the
TAp63b isoform
We first measured the effect of the six over-expressed p63
isoforms [26] or p53 on the transcription of previously described
groups of endogenous p63 and p53 target genes in transfected
HeLa cells [5]. The endogenous p63 target genes were activated
by ectopic expression of the longer TA a and b isoforms and not
by the shorter c isoform (Figure S2A in Text S1). The DN isoforms
were less active, although the b isoform did exhibit some level of
activation (Figure S2B in Text S1). None of these genes were
activated by p53, but p21 was activated around 10-fold (Figure
S2C in Text S1). While p53 did not activate p63 target genes, we
found that the TAp63c isoform efficiently activates p53 target
genes including p21 (Figure S2D in Text S1). These results
demonstrated that a cross-activation of the p53 target genes by
p63 can occur, although with marked preference for the shorter
TAp63c isoform, as previously reported [27].
We then decided to confirm which p63 isoforms regulated the
endogenous set of p63 target genes in Caski cells. We used
recombinant adenoviruses expressing both a and b isoforms of TA
and DNp63b that were previously found to be the most efficient in
activating p63 target genes in transfected HeLa cells (Figure S2A
and S2B in Text S1). Infection with an increasing multiplicity of
infection (m.o.i.) of the recombinant adenovirus expressing the
TAp63b isoform led to increased expression of the transcription
factor (Figure 4A and 4B, upper panels), coupled with corre-
sponding increases in mRNA expression of the endogenous set of
genes (Figure 4C). Activation ranges from 2-fold for notch1 to 20-
fold for ceacam1 with TAp63b (Figure 4C) while in contrast the
DNp63b isoform (Figure 4A and 4B lower panels) did not induce
significant changes in the basal mRNA levels of the p63 target
genes, a maximum 2-fold change being seen for the itga2 and lamb3
gene expression (Figure 4D). The TAp63a long isoform was
similarly inactive in this assay (Data not shown). Interestingly, we
found that overexpression of the TAp63b isoform, but not of the
DNp63b isoform, led to a decrease of about 3-fold of the
endogenous constitutive level of the DNp63a isoform through an
unknown mechanism (Figure 4B, upper panel). These results
unambiguously establish that the set of genes modulated in our
microarrays is composed of p63 target genes, likely activated most
efficiently by the TAp63b isoform in Caski cells.
We then wanted to extend our finding to other cervical
carcinoma cell lines and used SiHa also associated with HPV16.
We first demonstrated that repression of E6/E7 transcription by
E2C induced the same p63 target genes as in Caski cells as well as
the p53 target gene p21 (Figure S3A in Text S1). We also infected
SiHa cells with the recombinant adenoviruses expressing TA and
DN p63b isoforms using conditions where 100 % of the cells were
infected (Figure S3B in Text S1). This showed that expression of
TAp63b and not DNp63b, activated the p63 target genes (Figure
S3C in Text S1). Altogether these data strongly suggest that this
new p63 pathway is conserved in cervical squamous cell
carcinoma and that the adhesion genes are modulated by TAp63b
preferentially with no clear involvement of the DNp63 isoforms.
HPV18 E6 modulates the TAp63b isoform by accelerating
its degradation
We have shown that TAp63b is a transcriptional activator
whose activity is repressed by the HPV oncogenes in Caski cells.
Since expression of the viral oncogenes occurred through
polycistronic mRNA as previously discussed, we could not
separately repress E6 or E7 in our model system. However, the
putative down modulation of TAp63b described here is reminis-
cent of the down modulation of p53 by E6 in cervical cancer [28–
30], and we decided to verify the simpler hypothesis incriminating
E6 rather than E7 in p63 modulation. We tested whether HPV18
E6 could degrade TAp63b in our system by cotransfection with an
expression vector for HPV18 E6 into HeLa cells [29]. In the same
experiment we also cotransfected p53 as a positive control and
DNp63b to verify whether the TA isoform is preferentially
degraded. We performed these experiments in the presence of
cycloheximide to prevent protein synthesis. This revealed that
expression of HPV18 E6 accelerated the degradation of TAp63b
although often less efficiently than p53 (Figure 5A). The DNp63b
isoform remained quite stable, at least for the first hour of
cycloheximide treatment (Figure 5A). Thus E6 can induce
degradation of the TAp63b isoform, whilst the DN isoform seems
more resistant. Together with our finding that the TAp63b
isoform is an activator of p63 target genes in Caski cells, its
destabilization by E6, leading to transcriptional repression of the
target genes, thus mimics the situation previously reported for p53
in cervical cancer.
The next step was to ask whether this degradation of TAp63b
was mediated through interaction between TAp63b and E6 and
via the ubiquitin ligase E6AP, as demonstrated for p53 [30].
Interaction between Myc-tagged E6 and TAp63b was readily
detectable by coimmunoprecipitation in cotransfected HeLa cells
treated with lactacystin to inhibit protein degradation. P53 was
also coimmunoprecipitated with Myc-tagged E6, while the Myc-
tagged Cyclin B, used as a negative control, did not coimmuno-
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[31] to silence E6AP in HeLa cells cotransfected with E6 and
TAp63b. Interestingly silencing of the E6AP ubiquitin ligase did
not lead to stabilization of TAp63b (Figure 5C) while in the same
cells, endogenous p53 was stabilized about 10-fold, back to its
basal level in untreated cells (Figure 5C). This suggests the
Figure 4. The adhesion genes are activated by TAp63b but not by DNp63b in Caski cells. (A) Real-time PCR performed in Caski cells
infected with recombinant adenoviruses expressing GFP compared to TAp63b (upper panel) or DNp63b (lower panel) at increasing m.o.i. (20, 50 and
100). Levels of mRNA were given in arbitrary units (a.u) with the endogenous levels in GFP-infected cells set up at 1000. (B) Western Blots performed
in infected Caski cells as described in panel A. The protein levels correlate with the m.o.i. and over expression of TAp63b and not DNp63b led to a
decrease of the endogenous level of the DNp63a isoform as indicated by the quantification levels given below the western blot pictures. (C)
Modulation of the mRNA levels of adhesion genes detected by RT-PCR in Caski cells infected with an increasing m.o.i. of the recombinant adenovirus
expressing the TAp63b isoform compared to GFP. (D) Same experiments as in panel C with the adenovirus expressing the DNp63b isoform compared
to adenovirus expressing GFP. Levels of mRNA were calculated as in A (mean 6 SD, *p , 0.05). Data shown is representative of at least three
independent experiments.
doi:10.1371/journal.ppat.1002256.g004
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(A) TAp63b, DNp63b or p53 (as a positive control) were cotransfected with GFP expression vectors as controls for comparable transfection efficiency,
in HeLa cells, in the presence or absence of a HPV18 E6 expression plasmid. After 24 h, cycloheximide (CHX) was added to the medium and cells were
harvested at 0, 0.5, 1 or 2 h of treatment and analyzed by Western blotting with the p63, p53 and GFP antibodies as indicated. (B) Co-
immunoprecipitation of cotransfected TAp63b and Myc-HPV18 E6 or Myc-Cyclin B2 as a negative control, were done in HeLa cells while
cotransfection of Myc-HPV18 E6 and p53 was done as a positive control. (C) HeLa cells were transfected with control siRNA or E6AP siRNA for 20 h
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infected by recombinant adenoviruses expressing GFP alone, TAp63b or GFP-E2 as indicated at the top of the figure. Phase contrast microscopy was
performed on live cells, 24 h after infection with TAp63b recombinant adenovirus and 42 h with the E2 recombinant adenovirus at 10X magnification.
(B) Induction of TAp63 expression in SiHa cells infected by Ad-GFP-E2 that represses endogenous E6/E7 expression. Immunofluorescence of TAp63 is
revealed by the purified specific antibody against this isoform (Biolegend, Poly 6189) counterstained with Texas red. The GFP expression controlling
the infected cells is green while nuclei are stained in blue by DAPI.
doi:10.1371/journal.ppat.1002256.g006
and were then cotransfected with TAp63b, GFP and HPV18 E6 expressing vectors. After 24 h, cells were treated with CHX for 2 h, harvested and
analyzed by Western blot as described in panel A. E6AP siRNA efficiency was assessed through stabilization of the endogenous p53. (D) HeLa cells
were co-transfected with HPV18 E6 and TAp63b or p53 as in panel A, with or without an additional treatment of 6 h by Lactacystin. (E) Caski and SiHa
were either infected with E2 recombinant adenovirus to induce repression of E6/E7 transcription (-) or with the GFP (+). TA and DN p63 were detected
by specific purified antibodies from Biolegend (Poly 6189) and the 4A4 from Pharmingen respectively, while p53 was detected as in panel B. (F) Model
for the control of the p63 pathway in Caski cells. Quantification of the p53 and p63 expression, corrected by the GFP and actin controls, are given
under each western blot picture with time 0 (panels A and C) or the controls (panels D and E) set up at 1.
doi:10.1371/journal.ppat.1002256.g005
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TAp63b which was however stabilized 3.5-fold by the proteasome
inhibitor lactacystin as expected while p53 was stabilized 5-fold in
the same experiment (Figure 5D).
We then needed to verify whether repression of E6 and E7 and
subsequent stabilization of TAp63b could be detected in cervical
carcinoma cell lines SiHa and Caski. We infected the two cell lines
with the adenovirus expressing E2, as the best repressor of
oncogenic transcription (repression of more than 90% compared
to 60–70% of E6/E7 with siRNA) or adenovirus expressing GFP
as a negative control. Extremely efficient repression of E6 and E7
induced a strong stabilization of 3-fold of the p53 protein, as
expected, altogether with stabilization of 2 and 3.4-fold of the
TAp63b isoform in Caski and SiHa respectively (Figure 5E).
Ectopically expressed TAp63b appeared as a slightly lower
migrating band due to insertion of a shorter version of the protein
in the original expression vector as described [26] (Figure 5E).
These data show that the low level of the TAp63b protein is due to
its continuous degradation by E6, a situation reminiscent of p53
degradation. In the same Caski cells, we also observed slightly
reduced expression (about 20% reduction) of the endogenous
DNp63a isoform after E6/E7 repression and stabilization of
TAp63b (Figure 5E) as demonstrated earlier in cells infected with
the TAp63b recombinant adenovirus (Figure 4B, upper panel).
However, this was not observed in SiHa cells where endogenous
DNp63a is not detectable (Figure 5E). From these data we could
draw a model whereby p63 target genes are activated by TAp63b
which is targeted for degradation by E6; while DNp63a would
modulate other target genes that are not studied here (Figure 5F).
The overall effect of E6 expression in Caski is summarized by
repression of the adhesion genes, represented by notch1, and
activation of DNp63a, both by indirect mechanisms resulting from
the pivotal degradation of TAp63b by E6 (Figure 5F).
Repression of E6/E7 and expression of TAp63b increase
focal adhesion in cervical carcinoma cells
The next question was whether activation of adhesion genes
would stimulate phenotypic changes of TAp63b expressing cells.
Cervical carcinoma SiHa cells infected with TAp63b or E2
recombinant adenoviruses acquired star-like structure together with
enlargement of their cytoplasms (Figure 6A). In E2-expressing SiHa
cells, these morphological changes correlated with stabilization of
endogenous TAp63b as shown by immunofluorescence (Figure 6B)
and western blot (Figure S5A in Text S1). Immunofluorescent
labeling of vinculin and paxillin, markers of focal adhesion, showed
an increase in number and size of the labeled foci at the membrane
of E2-infected SiHa (Figure 7). In Caski cells, labeling of vinculin
clearly showed an increase in focal adhesion in TAp63b and E2
expressing cells which was drastically reduced by silencing of p63 in
E2 expressing cells, thus indicating that this increase in focal
adhesion is mediated by TAp63 (Figure 8). An increase in focal
adhesion was also seen in primary keratinocytes infected by the
recombinant adenovirus expressing TAp63b, although these cells
already present higher basal levels of focal adhesion than Caski
(Figure S4 in Text S1), while in contrast no activation of TAp63b
expression was detected in E2 expressing keratinocytes (Figure S5A
in Text S1). Increase of focal adhesion and reorganization in cell
membrane of E2 expressing SiHa and Caski cells were not
accompanied by an increased expression of paxillin and involucrin,
as shown by western blots (Figure S5B in Text S1). These results
therefore point to an indirect role of TAp63b in modulating focal
adhesion, which is in line with our previous findings since paxillin
and vincullin were not found among the p63 transcriptional target
genes. More work is needed however to fully characterize these
phenotypic changes associated with expression of the TAp63b
isoform and to understand the mechanism by which focal adhesion
is modulated. Altogether, we have demonstrated here for the first
time a strong involvement of the TAp63b isoform in formation of
focal adhesion in epithelial cells and its down modulation by
expression of the HPV E6 oncogene.
Discussion
The p63 transcription factors are either activators or repressors
of transcription depending on the isoforms expressed, the cell
Figure 7. E6/E7 repression by E2 induces focal adhesion in SiHa
cells. (A) SiHa cells grown on coverslips were infected by recombinant
adenoviruses expressing either GFP (left panels) or GFP-E2 (right panels)
at m.o.i. 100, in conditions where all the cells are infected and express
green fluorescent protein. Staining with the monoclonal antibody
against vinculin hVIN-1 (V9131, SIGMA) counterstained with anti-mouse
Alexa is shown in upper panels. The overlay picture of vinculin in red,
GFP in green and DNA in blue (DAPI) is shown in the lower panels. (B)
Same as in (A) but with the monoclonal antibody against paxilin 5H11
(ab3127, Abcam). Pictures were taken with a Zeiss confocal laser
scanning microscope at an original magnification of 40X.
doi:10.1371/journal.ppat.1002256.g007
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oncogenes E6 and E7 in cervical carcinoma modulates p63 target
genes in a unique way since an entire p63 target gene set was
activated while none were repressed. It should be noted that
activation of the p63 target genes in our system was generally
lower than that of p53 target genes, as if the regulatory pathways
leading to modulation of the p63 targets were less homogeneous.
Indeed, p63 is expressed as various isoforms which can interact
Figure 8. TAp63b ectopic expression and E6/E7 repression by E2 induce TAp63b-mediated focal adhesion in caski cells. Caski cells
grown on cover slips were infected by recombinant adenoviruses expressing GFP, GFP-E2 or TAp63b at m.o.i. 100 as indicated, in conditions where all
the cells are infected and express green fluorescent protein. Transfection with p63 siRNA was done in GFP and E2 infected cells as indicated. Staining
with the monoclonal antibody against vinculin hVIN-1 (V9131, SIGMA) counterstained with anti-mouse Alexa is shown. The overlay pictures of
vinculin in red and DNA in blue (DAPI) are shown. Pictures were taken with a Zeiss confocal laser scanning microscope at an original magnification of
40X.
doi:10.1371/journal.ppat.1002256.g008
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p53. This has led to an intricate situation where activators and
repressors are not well defined. For instance, DNp63 is usually
recognized as a repressor although it also contains a specific
activator domain [32,33], while TAp63 is mainly described as an
activator due to the presence of the long N-terminal transactiva-
tion domain. However, the longest TAp63a isoform also contains
a C-terminal domain which is a repressor of the TA domain, thus
leading to inefficient transcriptional activation [34]. The most
efficient activator so far described in the literature has been the
shortest isoform TAp63c but this was demonstrated with a group
of p53 target genes [27] as confirmed in our system. In contrast,
we demonstrated here that TAp63b can activate p63 target genes
in a specific manner in Caski and SiHa cervical carcinoma cell
lines. This finding is unexpected since the TAp63 isoforms have
not been detected in human epithelial cells and had not been
assigned specific roles in skin development [35], although TAp63
was recently shown to play an important role in regulating cellular
senescence and genomic instability [21]. Its depletion in skin
induces premature aging due to uncontrolled multiplication of skin
stem cells which is in line with a putative oncogenic role of
TAp63b depletion in cervical carcinomas.
Another major finding of our work is the fact that the HPV18
E6 oncogene can accelerate degradation of the TAp63b isoform,
although independently of the E6AP ubiquitin ligase which is
implicated in degradation of p53 [30]. TAp63 is known to be
degraded through the proteasomal pathway via its amino-terminal
TA domain [36,37], independent of MDM2 [36]. The Itch
ubiquitin ligase has been suggested as one of the major factors
controlling the stability of both the TA and DN p63 isoforms [38]
although it degrades the DN isoforms more efficiently [39,40]. As
for the putative roles of viral oncoproteins, it has been reported
that they are unable to interact with p63 or to noticeably modify
p63 activity [41]. Our work presents evidence that the high risk
HPV18 E6 oncoprotein can bind TAp63b and accelerates its
degradation. However and significantly, E6 uses a different
pathway than for the degradation of p53 and the ubiquitin ligase
involved in TAp63b degradation has yet to be identified. A
striking consequence of this finding is that repression of the
endogenous oncogenes induces stabilization of endogenous
TAp63b together with p53, in all cervical carcinoma cell lines
that we have examined including HeLa, Caski and SiHa. Another
consequence of our findings is that DNp63 does not seem
implicated in regulation of the anchorage independent growth in
cervical cancer which is surprising in light of its pivotal role in skin
homeostasis. In cervical carcinoma cells, stabilization of TAp63b
induces an increase in focal adhesion. In keratinocytes, we could
also show that overexpression of the b isoform increased focal
adhesion. However the basal level of focal adhesion is higher in
keratinocytes compared to cervical carcinoma cells and the best
expressed TAp63 in these cells is the c isoform. We infer from
these data that the c isoform is also probably able to modulate
focal adhesion but more work is needed to clarify this point.
The p53/p63 family of transcription factors also includes p73
and its various isoforms [42], which share identical binding sites
with p63 and can form heterotetrameric factors to concomitantly
bind the same sites if expressed at the same time [43]. The p73
transcription factors however, are not expressed in skin and have
no known roles in its homeostasis, while they play roles in
neurogenesis, inflammation, sensory pathways and osteoblastic
differentiation [44] as well as in genomic stability and tumor
suppression [45]. Since the present study mostly describes
modulation of a group of target genes involved in adhesion
pathways that are therefore directly linked to skin maintenance
and differentiation, it is presumed that p73 should not play a
dramatic role here. We cannot exclude however that some cross-
regulation could take place.
We have shown here that TAp63b activates genes involved in
cell adhesion and induces phenotypic changes in focal adhesion in
keratinocytes upon its ectopic expression. The bovine papilloma-
virus E6 protein has previously been shown to modulate focal
adhesion through direct interaction with paxillin [46,47]. We
cannot exclude that HPV E6 could also directly influence cell
adhesion in cervical carcinoma cells. However, we show here that
E6 induces a strong modulation of focal adhesion through
degradation of TAp63b. This novel role of E6 thereby participates
in oncogenic transformation of cervical carcinoma cells through
induction of anchorage independent growth. TAp63b therefore
appears as a tumor suppressor in our system, which is in
agreement with its recently reported roles in mouse models
[21,48,49]. This is, to our knowledge, the first time that TAp63b is
implicated in a human cancer, cervical carcinoma, which is one of
the leading causes of death by cancer in women worldwide.
Materials and Methods
Infection of Caski and SiHa cells with recombinant
adenoviruses
Recombinant adenoviruses expressing green fluorescent protein
(GFP) alone, GFP fused to HPV18 E2 protein deleted of its
transactivation domain (E2C) or E2 full-length were previously
described [50]. Recombinant adenoviruses expressing TAp63b or
DNp63b isoforms were prepared from the pIRES expression
plasmids containing the TAp63b or DNp63b gene followed by the
IRES sequence and the GFP gene. Recombinant adenoviruses
expressing the TA and DNp63a isoforms were a kind gift of Barry
Trink [26].
Cells were infected with purified adenoviruses expressing GFP,
GFP-E2 or GFP-E2C at a multiplicity of infection (m.o.i.) of 100
or 200 PFU/cell or with adenoviruses expressing GFP, TAp63b
or DNp63b at an m.o.i. of 20, 50 or 100 PFU/cell, as described
previously [4].When needed, 24 hours after infection, cyclohex-
imide was added at 100 mg/ml for up to 2 h and/or lactacystin
was administered at 10 mM for up to 6 hours.
Cell culture and transfections
HeLa, Caski and SiHa cells were grown using standard
procedures in a 37uC humidified incubator with 5% CO2. All
cell lines were grown in high-glucose Dulbecco’s modified Eagle’s
medium (Invitrogen) with 10% heat-inactivated fetal bovine
serum.
Plasmids were transfected using FuGENE HD (Roche)
according to the manufacturer’s instructions. Expression plasmids
for the six p63 isoforms were kindly provided by Barry Trink.
For siRNA transfection, DharmaFECT 1 (Thermo Scientific)
was used according to the manufacturer’s instructions.
The siRNA sequences used were:
HPV18 E6/E7 siRNA: GCAUGGAGAUACACCUACAdTdT
HPV16 E6/E7 siRNA: GAGCUGCAAACAACUAUACdTdT
Control siRNAs used in HPV16 positive cells (Caski) and in
HPV18 positive cells (HeLa) were HPV18 E6/E7 siRNA and
HPV16 E6/E7 siRNA respectively.
For p63 siRNA (which targets all p63 isoforms) and p53 siRNA, we
used ON-TARGETplus SMARTpools (Thermo Scientific), which are
pools of 4 different siRNAs for each gene with the following sequences:
p63 siRNAs: (UCUAUCAGAUUGAGCAUUA; GCACACA-
GACAAAUGAUU; CGACAGUCUUGUACAAUUU; GAU-
GAACUGUUAUACUUAC)
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CUGUGGGUUGAUU; GCAGUCAGAUCCUAGCGUC;
GGAGAAUAUUUCACCCUUC).
Microarray hybridization and analysis
The high density microarrays used in this study were the
Human Gene 1.0 ST array from Affymetrix, including 28,869
well-annotated genes with 764,885 distinct probes. A total of
200 ng of RNA for each experiment was amplified, terminally
labeled and used for hybridization according to the manufacturer’s
instructions (Affymetrix). The microarrays were washed and
stained using Fluidics Station (GenChip) and scanned using a
GeneArray 25000 Scanner. Data collected from each hybridiza-
tion experiment were analyzed and statistical analyses carried out
using Partek Genomics Suite software.
RNA isolation and quantitative RT-PCR
Total RNA was extracted using RNAEasy Mini Kit (Qiagen)
and a total of 2.5 mg of RNA were reverse transcribed with
Superscript II (Invitrogen) according to the manufacturer’s
instructions. From the resulting synthesized single-stranded cDNA,
1/100 was used for each Real-time PCR in the presence of 1 mM
of specific primers and Syber Green master mix (Applied
Biosystems). Quantitative PCR were performed with an
MX3005P sequence detection system (Stratagene). Each cDNA
was normalized to histone deacetylase 1 (HDAC1), glyceralde-
hyde-3-phosphate dehydrogenase (GADPH), and 18S ribosomal
RNA. PCR were performed in duplicate and fitted to standard
curves, providing mean cycle threshold values that were translated
into arbitrary units corresponding to mRNA levels. Data were






























Notch1: 59- GAGTGGGACCAACTGTGACAT-39;5 9-
CCGTTGACACAAGGGTT-39







All Real time PCR data are represented as mean 6 SD. Data
were analyzed using paired t test for comparison between two
groups. P Values under 0.05 were considered significant. All
experiments were done at least three times.
Western blot
Infected or transfected cells were collected 24 or 42 h post-
infection or post-transfection, and protein extracts were subjected
to electrophoresis before transfer onto nitrocellulose membranes.
The membranes were then incubated with antibodies specific for:
p63 (4A4, BD Pharmingen), TAp63 purified antibody (Biolegend
Poly 6189) or the monoclonal TAp63, a kind gift of Franck
McKeon, [35], p53 (DO-1, Santa-Cruz), GFP (TP401; Torrey
Pines Biolabs) or beta-actin (A2066, Sigma); and either mouse or
rabbit secondary antibodies coupled to peroxidase. Protein bands
were revealed using the Amersham ECL plus kit. Quantification of
western blots was done by measuring the relative intensity of the
bands compared to internal controls (GFP and or actin), the values
given are in arbitrary units.
Co-immunoprecipitation
Hela cells were co-transfected with TAp63b and Myc-E6
HPV18 or Myc-CyclinB2, as a negative control. As positive
control, HeLa cells were cotransfected with Myc-E6 HPV18 and
p53 expressing vectors. 20 h post-transfection, cells were treated
with 10 mM of lactacystin for 6 h. Cells were harvested and
proteins were extracted in an extraction buffer (300 mM NaCl,
50 mM Tris-HCl [pH 8], 0.5 % Nonidet P-40 [NP-40], 1 mM
EDTA, protease and phosphatase inhibitors) for 30 min at 4uC,
followed by centrifugation. Extracts containing 1 mg of total
proteins were immunoprecipitated with the rabbit anti-myc
antibody (A-14; Santa Cruz) 5 h at 4uC. After centrifugation,
beads were washed four times with 1 ml of extraction buffer.
Proteins from the beads and input (1/40 of total proteins) were
separated by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and analyzed in Western blot experiments.
For Western blot experiments, mouse anti-Myc (9E10; Santa
Cruz), mouse anti-p53 (DO-1; Santa Cruz) and mouse anti-pan-
p63 (4A4, BD Pharmingen) antibodies were used.
Immunofluorescence
Cells grown on cover slips were fixed at 4uC for 30 min with 2%
paraformaldehyde (v/v) and washed in PBS. Cells were then
permeabilized for 30 min at room temperature in PBS, 2% serum,
0.1% triton. After washing with PBS, the cells were incubated with
primary antibodies for 1 h at room temperature, washed 3 times
with PBS, 2% serum, followed by secondary antibodies for 1 h at
room temperature. After washing with PBS, cell nuclei were
stained with DAPI (Invitrogen). Antibodies against paxillin (clone
5H11, Abcam ab3127) and vinculin (clone hVIN-1, Sigma) and
TAp63 purified antibody (Biolegend Poly 6189) were used.
Secondary antibodies were fused to Alexa fluor 568 (Invitrogen).
Confocal fluorescent images were obtained by a Zeiss confocal
laser scanning microscope with a 40X objective.
Accession numbers
p63: *603273, p53: *191170, pRb: +180200, p73: *601990,
E2F1: *189971, p57kip2: *600856, p21: *116899, CENPA:
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*109770, Notch1: *190198, COL5A1: *120215, LAMB2:
*150325, FAT: *600976, FN1: +135600, FBN1: *134797,
GDF15: *605312, Sestrin: *606103, RRM2B: *604712, E6AP:
*601623, Paxillin: *602505, Vinculin: *193065, MDM2: +164785,
GADPH: *138400, HDAC: *601241, 18S: *180473.
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